More maintenance.

Neoadjuvant, cisplatin-based chemotherapy is preferred for muscle invasive urothelial carcinoma (MIBC). he role of adjuvant therapy (including immunotherapy) is unclear. Recently, the phase 3 IMvigor010 found that up to 1 year of adjuvant atezolizumab (a PD-L1 inhibitor) did not improve disease-free survival in patients with high risk, resected muscle invasive urothelial carcinoma. In CheckMate 274, 709 patients with resected muscle invasive urothelial carcinoma (79% bladder cancer) were randomized to placebo or nivolumab (a PD-1 inhibitor) for up to 1 year. In the overall population, adjuvant nivolumab nearly doubled median disease-free survival (DFS) from 10.8→ 20.8 months and increased 6-month DFS from 60.3→ 74.9%. This was driven by significant improvements in survival free from recurrence outside the urothelial tract and distant metastasis. | Bajorin, N Engl J Med 2021

Comments

  1. This is another testimony on how Chief Dr Lucky cured my HIV disease. Do you need a cure for your HIV disease? Do you want to be cured from your cancer disease? Or you want to be free from any type of disease. Kindly visit his website https://chiefdrluckyherbaltherapy.wordpress.com/ . He just cured my HIV disease and I’m very grateful to him, he is the only herbalist that can cure you.  
    WhatsApp number : +2348132777335 
    Via Email : chiefdrlucky@gmail.com
    Thank you all for reading,
    God bless"

    ReplyDelete
  2. This has been a really wonderful article. Many thanks for providing this information. Visit our website too girl kubet

    ReplyDelete

Post a Comment

Popular Posts